Beijing Honglin RoToFier has won the bid in the 5th Round Centralized Procurement of Drugs!

On June 23rd, the result of the 5th Round National Governmental Bid for Centralized Procurement of Drugs was released, RoToFier (Glipizide Extended Released Tablets) of Beijing Honglin pharma.Co.,Ltd. was one of the winners of the bid. It makes considerable contribution for National Medical & Social Care system, also it brings good news by giving supply of high-quality medication and lower economic burden for diabetes patients.

Region covered by the bid : Beijing, Shanxi, Inner Mongolia, Liaoning, Heilongjiang, Shanghai, Jiangsu, Fujian, Jiangxi, Shandong, Xinjiang ( Including Xinjiang Production and Construction Corps )

RoToFier (Glipizide Extended Release Tablets) , 1st Glipizide Extended Release Tablets Generic Drug Consistency Evaluation certified in China, is the new generation hypoglycemic drug self-developed by Beijing Honglin Pharmaceutical, the patent will not expire until 2029.

Along with superior extended & controlled-released technology, which builds up a knowledge-property platform based on osmotic-pump technology, Beijing Honglin Pharmaceutical, Co, Ltd. has already established an exclusive production system on the basis of osmotic-pump technology. Top of all, the assembly of the latest generation laser driller from the USA, equipped with brand new on-line surveillance system, enhances the quality level of each single tablet produced.

We “ Hongliners “, who carry the motto of “ Happy life, Healthy life “, are determined to the fabrication of the best medicine, to become the guardian of the health of all citizens by means of our edge - cutting technology and corporate advantages.